

Institutional Biosafety Committee

Jun-13-2025, via Zoom

Attendance

Members In Attendance

Member	Voting	Staff	Scientific	Affiliated
Cayabyab, Mark Ph.D.	Yes	Yes	Yes	Yes
Krueger, Robin Lynn Ph.D., M.P.H.	Yes	Yes	Yes	Yes
Murphy, Robert	Yes	No	No	No
Roldan, Janice M.B.A.	No	Yes	No	Yes
Tartar, Aurelien Ph.D.	Yes	Yes	Yes	Yes
Thompson, Jeffrey	Yes	Yes	Yes	Yes
Welmaker, Beth M.S.	Yes	Yes	Yes	Yes

Review of Meeting Minutes

March Meeting Minutes Approved (5 aye)

(MC not yet arrived to vote)

Annual Renewal Submissions

1. 2024-06-LS-02

Titled: Nebulized antioxidant/anti-pathogen agent and acute toxicity

Discussion:

MC not yet in attendance to vote.

Outcome: Approved

Votes for Outcome: 5

Votes Against Outcome: 0

Abstentions: 0

New Protocol Submissions

1. 2025-08-IB-01 (IBC New Submission)

Titled: Characterizing the influence of Toxoplasma gondii infection on synaptic protein expression using human neuroblastoma cells (SKNSH)

Discussion:

- SOP Section 8.3 - Must clarify the percentage of bleach that will be used to disinfect liquids.
- Inconsistencies in SOP Section 9.3 & 10.3. Must clarify whether waste will be autoclaved and placed in regular trash, or be picked up for disposal by a commercial service.

Outcome: Approved Pending Modification(s)

Votes for Outcome: 6

Votes Against Outcome: 0

Abstentions: 0

2. 2025-08-AR-01 (IBC New Submission)

Titled: Development of PD-TRAPs against PD-L1 and PD-L2 overexpressing cancer cells

Discussion:

- Need building location information.
- Work should be classified as BSL-1 not BSL-2.
- Provide spec sheets for CHO-K1 and HCC827 cells from commercial source(s)- are these considered BSL2?
- There was mention of PBMC – provide source and IRB exemption, if applicable.
- Remove III-D- classification as no DNA from RG2 or 3 is being cloned.
- Provide the strain of E. coli.
- For authentication of the PDX plasmid shown – has the gene been confirmed by sequencing? Was the gene created by Genewiz or in-house PCR cloning from what template?

Outcome: Requires Modifications to Secure Approval

Votes for Outcome: 6

Votes Against Outcome: 0

Abstentions: 0

3. 2025-06-MSal-01 (IBC New Submission)

Titled: Enhanced Bioreactor System for Modeling of Atherosclerosis

Discussion:

- The submitted SOP is a basic template, no specific information on this project or any of its experiments or requirements is provided.
- PI indicates Pathogenic/Infectious Agents will be used but does not define any. The project is assessed at BSL1 and seems to consist of little more than tissue cultures. It's not clear what will be done with the cell cultures, but does not appear to require an IBC approval.
- Where will culture of cells take place? Why would aerosols not be generated?
- What procedures will be used to minimize splashes and spills? How will these inevitable situations be cleaned up?
- PI indicates use of incubator in CCR 470D for bioreactor experiments. No incubator installed in specified location. Define the bioreactor experiments.
- PI indicates this work will be done in Dr. TK's lab. Does TK have knowledge of this?

IMPORTANT NOTE: This protocol was NOT APPROVED and will be re-reviewed once modifications are submitted to determine if proposed research is exempt from IBC review and approval.

Outcome: Not Approved

Votes for Outcome: 6

Votes Against Outcome: 0

Abstentions: 0

Protocol Amendments

1. 2024-10-NG-02

Titled: Ketone Bodies-Mediated Cardiometabolic Adaptation via long noncoding RNAs

Discussion:

- Must provide spec sheet from vendor providing the AAV vectors. Include map, sequence, and how the AAV vector was attenuated from the wild type.
- Does the vendor recommend use of attenuated rAAV under BSL-2?
- SOP missing below:
 - Inclusion of use of BSL-2 stickers for transporting materials.
 - Statement indicating how much AAV will be produced and what volume.
 - How much AAV and concentration per experiment.

Outcome: Approved Pending Modification(s)

Votes for Outcome: 6

Votes Against Outcome: 0

Abstentions: 0

2. 2023-04-MS-01

Titled: Health Effects of the Fluoride and Fluorinated Pollutants (PFAS) on tooth development

Discussion:

Outcome: Approved

Votes for Outcome: 6

Votes Against Outcome: 0

Abstentions: 0

Other Business

- IBC was informed of new NIH Notice stating that all IBC rosters will now be publicly available. IBC chair, BSO and IBC coordinator contact information will also be publicly available. In addition, IBC meeting minutes will also have to be publicly posted once approved by the IBC. These minutes will be the first to be posted publicly after approved at our next quarterly meeting.
- BW to schedule tours of facilities for our external community members.